| Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ... New England Journal of Medicine 379 (2), 111-121, 2018 | 2046 | 2018 |
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial J Baselga, I Bradbury, H Eidtmann, S Di Cosimo, E De Azambuja, C Aura, ... The Lancet 379 (9816), 633-640, 2012 | 1584 | 2012 |
| Prospective validation of a 21-gene expression assay in breast cancer JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ... New England Journal of Medicine 373 (21), 2005-2014, 2015 | 1505 | 2015 |
| Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor–positive metastatic breast cancer S Johnston, J Pippen Jr, X Pivot, M Lichinitser, S Sadeghi, V Dieras, ... Journal of Clinical Oncology 27 (33), 5538-5546, 2009 | 1238 | 2009 |
| Adjuvant exemestane with ovarian suppression in premenopausal breast cancer O Pagani, MM Regan, BA Walley, GF Fleming, M Colleoni, I Láng, ... New England Journal of Medicine 371 (2), 107-118, 2014 | 877 | 2014 |
| Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer KR Hess, K Anderson, WF Symmans, V Valero, N Ibrahim, JA Mejia, ... Journal of clinical oncology 24 (26), 4236-4244, 2006 | 849 | 2006 |
| High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial AJM Ferreri, M Reni, M Foppoli, M Martelli, GA Pangalis, M Frezzato, ... The Lancet 374 (9700), 1512-1520, 2009 | 714 | 2009 |
| Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ... Clinical cancer research 20 (7), 1757-1767, 2014 | 678 | 2014 |
| Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment ES Thomas, HL Gomez, RK Li, HC Chung, LE Fein, VF Chan, J Jassem, ... Journal of Clinical Oncology 25 (33), 5210-5217, 2007 | 659 | 2007 |
| A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer C Hatzis, L Pusztai, V Valero, DJ Booser, L Esserman, A Lluch, T Vidaurre, ... Jama 305 (18), 1873-1881, 2011 | 649 | 2011 |
| Planning cancer control in Latin America and the Caribbean PE Goss, BL Lee, T Badovinac-Crnjevic, K Strasser-Weippl, ... The lancet oncology 14 (5), 391-436, 2013 | 627 | 2013 |
| Tailoring adjuvant endocrine therapy for premenopausal breast cancer PA Francis, O Pagani, GF Fleming, BA Walley, M Colleoni, I Láng, ... New England Journal of Medicine 379 (2), 122-137, 2018 | 620 | 2018 |
| A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma O Hamid, H Schmidt, A Nissan, L Ridolfi, S Aamdal, J Hansson, M Guida, ... Journal of translational medicine 9, 1-16, 2011 | 612 | 2011 |
| Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy HCF Moore, JM Unger, KA Phillips, F Boyle, E Hitre, D Porter, PA Francis, ... New England Journal of Medicine 372 (10), 923-932, 2015 | 604 | 2015 |
| Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer A Di Leo, HL Gomez, Z Aziz, Z Zvirbule, J Bines, MC Arbushites, ... Journal of Clinical Oncology 26 (34), 5544, 2008 | 561 | 2008 |
| Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets JM Balko, JM Giltnane, K Wang, LJ Schwarz, CD Young, RS Cook, ... Cancer discovery 4 (2), 232-245, 2014 | 545 | 2014 |
| Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study H Gacaferi, GS Collaborative, COVIDSurg Collaborative Anaesthesia 76 (6), 2021 | 537* | 2021 |
| RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune … S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, ... Clinical Cancer Research 22 (6), 1499-1509, 2016 | 531 | 2016 |
| MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation K Lee, JM Giltnane, JM Balko, LJ Schwarz, AL Guerrero-Zotano, ... Cell metabolism 26 (4), 633-647. e7, 2017 | 514 | 2017 |
| Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer JA Sparano, RJ Gray, PM Ravdin, DF Makower, KI Pritchard, KS Albain, ... New England journal of medicine 380 (25), 2395-2405, 2019 | 437 | 2019 |
Joseph A. PintoOncosalud-AUNAVerified email at gecoperu.org
